Breaks Categories: News

FridayJan 19, 2024 12:53 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has appointed a biotech veteran to its board of directors. The company announced that Amy Mahery, a highly accomplished biopharmaceutical industry executive, will join the company’s board effective upon completion of financing. With more than 20 years of experience working with large and small companies in common and rare conditions, Mahery brings impressive expertise in the commercialization and launch of drugs in varied therapeutic areas, including oncology, neurology, and immunology, to her new responsibilities.…

Continue Reading

ThursdayJan 18, 2024 1:01 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reaches Planned Enrollment Berubicin Study for the Treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has completed enrollment in its global potentially pivotal study evaluating Berubicin. According to the announcement, the study has enrolled 247 patients across 46 clinical trial sites in the United States, Italy, France, Spain and Switzerland. A novel anthracycline, Berubicin appears to be the first anthracycline to cross the blood-brain barrier for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. The Berubicin study is a multicenter, open-label, randomized controlled study…

Continue Reading

TuesdayJan 16, 2024 3:26 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Provides Update on Litigation

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today provided an update regarding its litigation with GBB Drink Lab Inc. (“GBB”). In May 2023, GBB filed a lawsuit against FSD Pharma alleging a material breach of a mutual nondisclosure agreement and trade secret misappropriation. FSD Pharma has categorically denied these allegations and filed a motion to dismiss the lawsuit. On Jan. 8, 2024, the court denied the motion to dismiss, which means only that FSD Pharma will now proceed with discovery. The company is confident that…

Continue Reading

TuesdayJan 16, 2024 2:38 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlined key accomplishments from 2023 and provided key strategic priorities for 2024. “In 2023, we experienced significant progress in both InMed’s pharmaceutical drug development and in BayMedica’s health and wellness initiatives. Our primary accomplishments throughout the year included a number of key milestones, such as the completion of a phase 2 clinical trial and the launch of two new preclinical programs targeting the treatment of Alzheimer’s disease and age-related macular degeneration (‘AMD’),” said Eric A. Adams, InMed president and CEO.…

Continue Reading

TuesdayJan 16, 2024 2:27 pm

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Releases CEO Shareholder Message

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has released a message for its shareholders from CEO Mark Dybul. In the message, Dybul provides an update about key developments the company experienced during 2023, including signing a definitive agreement to combine with the European-based, cutting-edge artificial-intelligence (“AI”) company GEDi Cube; GEDi Cube’s partnership with NVIDIA to expand its multiomic capabilities to multimodal; and consistently achieving “the holy grail of cancer research” in preclinical studies. The company has also scheduled a shareholder meeting on Jan. 25, 2024, to vote…

Continue Reading

FridayJan 12, 2024 2:30 pm

BioMedNewsBreaks — Bruush Oral Care Inc. (NASDAQ: BRSH) Closes Private Placement, Enters into Purchase Agreement

Bruush Oral Care (NASDAQ: BRSH), an oral-care company that is disrupting the space by reducing the barriers between consumers and access to premium oral-care products, has closed on a private placement transaction and a registration rights agreement with Generating Alpha Ltd. for aggregate gross proceeds of $500,000; the company also entered into another securities purchase agreement with Generating Alpha. According to the filing with the U.S. Securities and Commission, Bruush Oral Care has agreed to sell a convertible promissory note in an aggregate principal amount of up to $6 million. EF Hutton acted as placement agent for the financing. To…

Continue Reading

FridayJan 12, 2024 2:09 pm

BioMedNewsBreaks — SOBR Safe Inc. (NASDAQ: SOBR) Partners with Navix Health to Provide Next-Generation Digital Healthcare Platform

SOBRSafe (NASDAQ: SOBR), a company that is pioneering noninvasive, humane and hygienic alcohol detection with a priority on safety, support and accountability, has been selected by Navix Health, a leading provider of innovative healthcare technologies, as its exclusive alcohol data partner. According to the announcement, Navix Health will integrate SOBRsafe's advanced alcohol monitoring technology into its proprietary Navix Hub(TM). The exclusive hub is a fully unified facility and practice management software for behavioral health. The integration of the SOBRsafe technology, which will enable Navix Hub users to augment current operations with touch-based alcohol monitoring, is aimed to enhance patient care,…

Continue Reading

TuesdayJan 09, 2024 1:27 pm

BioMedNewsBreaks– SOHM Inc. (SHMN) Announces Filing of Provisional Patent for ABBIE Smart Gene Editing Technology

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, has filed a provisional patent application on its ABBIE Smart Gene-Editing platform. According to the announcement, the platform uses the latest enzymes and guide RNAs to resolve off-target gene-editing limitations. Gene therapy modifies or manipulates the expression of a gene or alters the biological properties of living cells for therapeutic use and has become a critical tool for treating genetic diseases. One of the challenges of gene therapy, however, is ensuring that gene edits happen at the intended site and not…

Continue Reading

TuesdayJan 09, 2024 1:17 pm

BioMedNewsBreaks – Branded Legacy Inc. (BLEG) Acquires All In Extracts LLC

Branded Legacy (OTC: BLEG), (soon to be known as Royal Enterprises Inc.), a burgeoning company in the pharmaceutical biotechnology sector, today announced its strategic acquisition of All In Extracts, a pioneering entity focused on medicinal ethnobotany. The milestone deal amplifies Branded Legacy’s focus on innovation, expansion and collaborative growth within the biotech community. “As soon as I met with the All In team, I knew something great was in the making,” said Branded Legacy CEO David Oswald. “It is a rare enough thing to find a company motivated primarily by the positive impact they can make on society. We are…

Continue Reading

MondayJan 08, 2024 2:19 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Significant Positive Results from LTE VISIONARY-MS Trial

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including (“ALS”) and multiple sclerosis (“MS”), today reported new CNM-Au8(R) results from the long-term open label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of follow-up. After completion of the double-blind period, study participants were offered to continue on CNM-Au8 30mg for up to an additional 96-weeks in the LTE. Analyses were reported for the modified intent…

Continue Reading